Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;28(5):535-42.
doi: 10.1007/s10637-009-9281-1. Epub 2009 Jun 26.

Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib

Ansgar Brüning  1 , Petra Burger, Marianne Vogel, Andrea Gingelmaier, Klaus Friese, Alexander Burges
Affiliations

Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib

Ansgar Brüning et al. Invest New Drugs. 2010 Oct.

Abstract

The HIV protease inhibitor nelfinavir is an investigational drug for cancer treatment. We have previously demonstrated induction of apoptosis by nelfinavir even in chemo-resistant ovarian cancer cells. In contrast to the pro-apoptotic effect of nelfinavir on human cancer cells, we noticed a significant upregulation of the anti-apoptotic mitochondrial membrane protein mcl-1 by nelfinavir, resulting in a mitochondria-independent induction of apoptosis. Upregulation of mcl-1 was associated with enhanced phosphorylation of both mcl-1 and of ERK1/2 (extracellular signal-regulated kinases 1/2). ERK1/2 enhanced stability of mcl-1 protein expression by serine-163 phosphorylation. The combination of nelfinavir with sorafenib, a clinically applied inhibitor of the RAS/RAF/ERK1/2 pathway, inhibited nelfinavir-induced ERK1/2 activation and mcl-1 protein upregulation. Further, the combination of nelfinavir with sorafenib induced mitochondrial membrane potential disruption and resulted in an improved activity of nelfinavir on ovarian cancer cells. Thus, a combination of these two investigational anti-cancer drugs could be of interest especially because of their unique mechanism of apoptosis induction even in otherwise chemo-resistant human cancer cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Cell Mol Life Sci. 2009 Apr;66(8):1326-36 - PubMed
    1. Lancet Oncol. 2009 Jan;10(1):61-71 - PubMed
    1. Expert Opin Investig Drugs. 2008 Oct;17(10):1501-16 - PubMed
    1. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9 - PubMed
    1. Cancer Chemother Pharmacol. 2008 Nov;62(6):1055-64 - PubMed

Publication types

MeSH terms

LinkOut - more resources